Author Archives: Patricia Inacio PhD

Ovid’s OV101 Earns FDA’s Fast Track Designation

The U.S. Food and Drug Administration (FDA) awarded a fast track designation to Ovid Therapeutics’ OV101 for the treatment of Angelman syndrome. The designation allows for expedited development and review of therapeutics for serious diseases with high unmet medical need. “This designation is an important milestone for both Ovid…

Genomic Recycling May Help Explain Our Unique Non-Coding Genome

Throughout evolution, genomic recycling of protein-coding genes gave rise to part of non-coding genes within our genome, known as long non-coding RNAs, or lncRNAs, a Weizmann Institute of Science study suggests. The findings will help scientists understand the role of lncRNAs in healthy and diseased conditions, such as Angelman…

Revised Panorama Prenatal Test More Accurately Identifies Angelman Syndrome and Other Genetic Disorders, Study Shows

A new, revised protocol of the non-invasive prenatal test (NIPT) Panorama identifies genetic abnormalities underlying Angelman and four other syndromes with higher accuracy and efficiency than the original test, a study found. The study, “Clinical Experience with a Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Five Clinically Significant…